As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works best has gained importance.

Germany’s Formycon has announced details of one of its previously undisclosed development projects in the shape of FYB208, a ...

The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous ...

Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...

Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...

Nasal polyposis involves noncancerous growths in the nasal and sinus linings, closely associated with chronic rhinosinusitis. Patients often experience symptoms like congestion, loss of smell, and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...

Skin regeneration: Though less directly tied to rhinitis, external nasal defects from surgery or chronic inflammation can be ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...